Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $2.49 billion. The enterprise value is $3.42 billion.
| Market Cap | 2.49B |
| Enterprise Value | 3.42B |
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 48.18 million shares outstanding. The number of shares has decreased by -2.97% in one year.
| Current Share Class | 48.18M |
| Shares Outstanding | 48.18M |
| Shares Change (YoY) | -2.97% |
| Shares Change (QoQ) | -2.27% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 112.70% |
| Float | 47.60M |
Valuation Ratios
The trailing PE ratio is 15.78 and the forward PE ratio is 10.40. Haemonetics's PEG ratio is 0.86.
| PE Ratio | 15.78 |
| Forward PE | 10.40 |
| PS Ratio | 1.99 |
| Forward PS | 1.83 |
| PB Ratio | 2.94 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.17 |
| P/OCF Ratio | 11.00 |
| PEG Ratio | 0.86 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.26, with an EV/FCF ratio of 18.09.
| EV / Earnings | 20.95 |
| EV / Sales | 2.54 |
| EV / EBITDA | 9.26 |
| EV / EBIT | 13.11 |
| EV / FCF | 18.09 |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 1.39.
| Current Ratio | 1.72 |
| Quick Ratio | 0.93 |
| Debt / Equity | 1.39 |
| Debt / EBITDA | 3.32 |
| Debt / FCF | 6.48 |
| Interest Coverage | 6.53 |
Financial Efficiency
Return on equity (ROE) is 18.27% and return on invested capital (ROIC) is 7.57%.
| Return on Equity (ROE) | 18.27% |
| Return on Assets (ROA) | 6.52% |
| Return on Invested Capital (ROIC) | 7.57% |
| Return on Capital Employed (ROCE) | 13.52% |
| Revenue Per Employee | $445,268 |
| Profits Per Employee | $54,031 |
| Employee Count | 3,023 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.51 |
Taxes
In the past 12 months, Haemonetics has paid $47.19 million in taxes.
| Income Tax | 47.19M |
| Effective Tax Rate | 22.42% |
Stock Price Statistics
The stock price has decreased by -30.36% in the last 52 weeks. The beta is 0.40, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -30.36% |
| 50-Day Moving Average | 71.35 |
| 200-Day Moving Average | 71.17 |
| Relative Strength Index (RSI) | 20.72 |
| Average Volume (20 Days) | 1,024,713 |
Short Selling Information
The latest short interest is 3.08 million, so 6.39% of the outstanding shares have been sold short.
| Short Interest | 3.08M |
| Short Previous Month | 3.66M |
| Short % of Shares Out | 6.39% |
| Short % of Float | 6.47% |
| Short Ratio (days to cover) | 5.65 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.35 billion and earned $163.34 million in profits. Earnings per share was $3.28.
| Revenue | 1.35B |
| Gross Profit | 791.12M |
| Operating Income | 261.06M |
| Pretax Income | 146.99M |
| Net Income | 163.34M |
| EBITDA | 369.57M |
| EBIT | 261.06M |
| Earnings Per Share (EPS) | $3.28 |
Balance Sheet
The company has $293.93 million in cash and $1.23 billion in debt, giving a net cash position of -$931.36 million or -$19.33 per share.
| Cash & Cash Equivalents | 293.93M |
| Total Debt | 1.23B |
| Net Cash | -931.36M |
| Net Cash Per Share | -$19.33 |
| Equity (Book Value) | 882.30M |
| Book Value Per Share | 18.32 |
| Working Capital | 381.75M |
Cash Flow
In the last 12 months, operating cash flow was $226.54 million and capital expenditures -$37.38 million, giving a free cash flow of $189.17 million.
| Operating Cash Flow | 226.54M |
| Capital Expenditures | -37.38M |
| Free Cash Flow | 189.17M |
| FCF Per Share | $3.93 |
Margins
Gross margin is 58.77%, with operating and profit margins of 19.39% and 12.13%.
| Gross Margin | 58.77% |
| Operating Margin | 19.39% |
| Pretax Margin | 15.64% |
| Profit Margin | 12.13% |
| EBITDA Margin | 27.46% |
| EBIT Margin | 19.39% |
| FCF Margin | 14.05% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.97% |
| Shareholder Yield | 2.97% |
| Earnings Yield | 6.56% |
| FCF Yield | 7.59% |
Analyst Forecast
The average price target for Haemonetics is $86.73, which is 67.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $86.73 |
| Price Target Difference | 67.92% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.7 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.7 |
| Piotroski F-Score | 6 |